Global Human Endostatin

Human Endostatin Comprehensive Study by Type (Idiopathic, Paraneoplastic), Application (Medical Care, Scientific Research, Others), Distribution Channel (Direct, Indirect) Players and Region - Global Market Outlook to 2028

Human Endostatin Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Human Endostatin
Human Endostatin is a type of Cleavage product which has a structure of carboxyl-terminal. It is naturally present in different volumes in liver, lung and kidney. Human Endostatin is popular because of its high anti-angiogenic properties. They have also been proved to be effective against late stage Non-Small-Cell Lung Carcinoma. The increasing investment in research and development of endostatin is said to benefit in growth of its market. Although lack of sufficient skilled professionals operating in this field, is a huge hampering factor for the accelerated growth of the human endostatin market. Geographically, North America is the prominent most market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer Inc. (United States), Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan), Thermo Fisher Scientific (United States), Novus Biologicals (United States), Yantai Medgenn Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Onyx Pharmaceuticals, Inc. (United States), Novartis AG (Switzerland), Biocon Limited (India) and PeproTech, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Genexine, Inc. (South Korea), EntreMed, Inc. (United States) and R&D Systems, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Human Endostatin market by Type (Idiopathic and Paraneoplastic), Application (Medical Care, Scientific Research and Others) and Region.



On the basis of geography, the market of Human Endostatin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Direct will boost the Human Endostatin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Medical Applications is the Most Dominant Segment

Market Growth Drivers:
High Investments in Research and Development of Endostatin to Explore Potential Applications and Increases in Diseases Associated with Liver, Lung, and Kidney

Challenges:
Lack of Skilled Professionals Working in Human Endostatin Market

Restraints:
The Human Endostatin is Still Relatively in Early Stages of Development

Opportunities:
Research should be made to Counter Rising Rate of Cancer Patients

Market Leaders and their expansionary development strategies
In 2020, Thermo Fisher Scientific, American Scientific Instrument, reagents and consumable manufacturer along with providing medical software solutions has announced completion of acquisition of Phitonex, Inc. Phitonex has recently been in news for its development of spectral dye platform as well as other products catering advanced cell therapy. The acquisition of Phitonex is looked as complementary to Thermo Fisher’s existing cell and protein analysis tools.
In 2020, Pfizer Inc., Multinational Pharmaceutical Giant which recently established itself as one of the developers of Covid-19 vaccines, which is also said to be one of the highest efficacy vaccines. Pfizer has announced completion of merger of its Upjohn Business with Mylan N.V. to form a new entity Viatris Inc. This move is set to accelerate the medicinal drug discovery and development, as well as add value to the investors.


Key Target Audience
Human Endostatin Manufacturers, Suppliers and Distributors, Raw Material Suppliers, New Entrants/Investors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Idiopathic
  • Paraneoplastic
By Application
  • Medical Care
  • Scientific Research
  • Others
By Distribution Channel
  • Direct
  • Indirect

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Investments in Research and Development of Endostatin to Explore Potential Applications
      • 3.2.2. Increases in Diseases Associated with Liver, Lung, and Kidney
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professionals Working in Human Endostatin Market
    • 3.4. Market Trends
      • 3.4.1. Medical Applications is the Most Dominant Segment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Endostatin, by Type, Application, Distribution Channel and Region (value and volume ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Human Endostatin (Value)
      • 5.2.1. Global Human Endostatin by: Type (Value)
        • 5.2.1.1. Idiopathic
        • 5.2.1.2. Paraneoplastic
      • 5.2.2. Global Human Endostatin by: Application (Value)
        • 5.2.2.1. Medical Care
        • 5.2.2.2. Scientific Research
        • 5.2.2.3. Others
      • 5.2.3. Global Human Endostatin by: Distribution Channel (Value)
        • 5.2.3.1. Direct
        • 5.2.3.2. Indirect
      • 5.2.4. Global Human Endostatin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Human Endostatin (Volume)
      • 5.3.1. Global Human Endostatin by: Type (Volume)
        • 5.3.1.1. Idiopathic
        • 5.3.1.2. Paraneoplastic
      • 5.3.2. Global Human Endostatin by: Application (Volume)
        • 5.3.2.1. Medical Care
        • 5.3.2.2. Scientific Research
        • 5.3.2.3. Others
      • 5.3.3. Global Human Endostatin by: Distribution Channel (Volume)
        • 5.3.3.1. Direct
        • 5.3.3.2. Indirect
      • 5.3.4. Global Human Endostatin Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
  • 6. Human Endostatin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novus Biologicals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Yantai Medgenn Co., Ltd. (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Intas Pharmaceuticals Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Onyx Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biocon Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. PeproTech, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Human Endostatin Sale, by Type, Application, Distribution Channel and Region (value and volume ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Human Endostatin (Value)
      • 7.2.1. Global Human Endostatin by: Type (Value)
        • 7.2.1.1. Idiopathic
        • 7.2.1.2. Paraneoplastic
      • 7.2.2. Global Human Endostatin by: Application (Value)
        • 7.2.2.1. Medical Care
        • 7.2.2.2. Scientific Research
        • 7.2.2.3. Others
      • 7.2.3. Global Human Endostatin by: Distribution Channel (Value)
        • 7.2.3.1. Direct
        • 7.2.3.2. Indirect
      • 7.2.4. Global Human Endostatin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Human Endostatin (Volume)
      • 7.3.1. Global Human Endostatin by: Type (Volume)
        • 7.3.1.1. Idiopathic
        • 7.3.1.2. Paraneoplastic
      • 7.3.2. Global Human Endostatin by: Application (Volume)
        • 7.3.2.1. Medical Care
        • 7.3.2.2. Scientific Research
        • 7.3.2.3. Others
      • 7.3.3. Global Human Endostatin by: Distribution Channel (Volume)
        • 7.3.3.1. Direct
        • 7.3.3.2. Indirect
      • 7.3.4. Global Human Endostatin Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Endostatin: by Type(USD Million)
  • Table 2. Human Endostatin Idiopathic , by Region USD Million (2017-2022)
  • Table 3. Human Endostatin Paraneoplastic , by Region USD Million (2017-2022)
  • Table 4. Human Endostatin: by Application(USD Million)
  • Table 5. Human Endostatin Medical Care , by Region USD Million (2017-2022)
  • Table 6. Human Endostatin Scientific Research , by Region USD Million (2017-2022)
  • Table 7. Human Endostatin Others , by Region USD Million (2017-2022)
  • Table 8. Human Endostatin: by Distribution Channel(USD Million)
  • Table 9. Human Endostatin Direct , by Region USD Million (2017-2022)
  • Table 10. Human Endostatin Indirect , by Region USD Million (2017-2022)
  • Table 11. South America Human Endostatin, by Country USD Million (2017-2022)
  • Table 12. South America Human Endostatin, by Type USD Million (2017-2022)
  • Table 13. South America Human Endostatin, by Application USD Million (2017-2022)
  • Table 14. South America Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 15. Brazil Human Endostatin, by Type USD Million (2017-2022)
  • Table 16. Brazil Human Endostatin, by Application USD Million (2017-2022)
  • Table 17. Brazil Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 18. Argentina Human Endostatin, by Type USD Million (2017-2022)
  • Table 19. Argentina Human Endostatin, by Application USD Million (2017-2022)
  • Table 20. Argentina Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 21. Rest of South America Human Endostatin, by Type USD Million (2017-2022)
  • Table 22. Rest of South America Human Endostatin, by Application USD Million (2017-2022)
  • Table 23. Rest of South America Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 24. Asia Pacific Human Endostatin, by Country USD Million (2017-2022)
  • Table 25. Asia Pacific Human Endostatin, by Type USD Million (2017-2022)
  • Table 26. Asia Pacific Human Endostatin, by Application USD Million (2017-2022)
  • Table 27. Asia Pacific Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 28. China Human Endostatin, by Type USD Million (2017-2022)
  • Table 29. China Human Endostatin, by Application USD Million (2017-2022)
  • Table 30. China Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 31. Japan Human Endostatin, by Type USD Million (2017-2022)
  • Table 32. Japan Human Endostatin, by Application USD Million (2017-2022)
  • Table 33. Japan Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 34. India Human Endostatin, by Type USD Million (2017-2022)
  • Table 35. India Human Endostatin, by Application USD Million (2017-2022)
  • Table 36. India Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 37. South Korea Human Endostatin, by Type USD Million (2017-2022)
  • Table 38. South Korea Human Endostatin, by Application USD Million (2017-2022)
  • Table 39. South Korea Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 40. Taiwan Human Endostatin, by Type USD Million (2017-2022)
  • Table 41. Taiwan Human Endostatin, by Application USD Million (2017-2022)
  • Table 42. Taiwan Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 43. Australia Human Endostatin, by Type USD Million (2017-2022)
  • Table 44. Australia Human Endostatin, by Application USD Million (2017-2022)
  • Table 45. Australia Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 46. Rest of Asia-Pacific Human Endostatin, by Type USD Million (2017-2022)
  • Table 47. Rest of Asia-Pacific Human Endostatin, by Application USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 49. Europe Human Endostatin, by Country USD Million (2017-2022)
  • Table 50. Europe Human Endostatin, by Type USD Million (2017-2022)
  • Table 51. Europe Human Endostatin, by Application USD Million (2017-2022)
  • Table 52. Europe Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 53. Germany Human Endostatin, by Type USD Million (2017-2022)
  • Table 54. Germany Human Endostatin, by Application USD Million (2017-2022)
  • Table 55. Germany Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 56. France Human Endostatin, by Type USD Million (2017-2022)
  • Table 57. France Human Endostatin, by Application USD Million (2017-2022)
  • Table 58. France Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 59. Italy Human Endostatin, by Type USD Million (2017-2022)
  • Table 60. Italy Human Endostatin, by Application USD Million (2017-2022)
  • Table 61. Italy Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 62. United Kingdom Human Endostatin, by Type USD Million (2017-2022)
  • Table 63. United Kingdom Human Endostatin, by Application USD Million (2017-2022)
  • Table 64. United Kingdom Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 65. Netherlands Human Endostatin, by Type USD Million (2017-2022)
  • Table 66. Netherlands Human Endostatin, by Application USD Million (2017-2022)
  • Table 67. Netherlands Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 68. Rest of Europe Human Endostatin, by Type USD Million (2017-2022)
  • Table 69. Rest of Europe Human Endostatin, by Application USD Million (2017-2022)
  • Table 70. Rest of Europe Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 71. MEA Human Endostatin, by Country USD Million (2017-2022)
  • Table 72. MEA Human Endostatin, by Type USD Million (2017-2022)
  • Table 73. MEA Human Endostatin, by Application USD Million (2017-2022)
  • Table 74. MEA Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 75. Middle East Human Endostatin, by Type USD Million (2017-2022)
  • Table 76. Middle East Human Endostatin, by Application USD Million (2017-2022)
  • Table 77. Middle East Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 78. Africa Human Endostatin, by Type USD Million (2017-2022)
  • Table 79. Africa Human Endostatin, by Application USD Million (2017-2022)
  • Table 80. Africa Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 81. North America Human Endostatin, by Country USD Million (2017-2022)
  • Table 82. North America Human Endostatin, by Type USD Million (2017-2022)
  • Table 83. North America Human Endostatin, by Application USD Million (2017-2022)
  • Table 84. North America Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 85. United States Human Endostatin, by Type USD Million (2017-2022)
  • Table 86. United States Human Endostatin, by Application USD Million (2017-2022)
  • Table 87. United States Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 88. Canada Human Endostatin, by Type USD Million (2017-2022)
  • Table 89. Canada Human Endostatin, by Application USD Million (2017-2022)
  • Table 90. Canada Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 91. Mexico Human Endostatin, by Type USD Million (2017-2022)
  • Table 92. Mexico Human Endostatin, by Application USD Million (2017-2022)
  • Table 93. Mexico Human Endostatin, by Distribution Channel USD Million (2017-2022)
  • Table 94. Human Endostatin Sales: by Type(K Tons)
  • Table 95. Human Endostatin Sales Idiopathic , by Region K Tons (2017-2022)
  • Table 96. Human Endostatin Sales Paraneoplastic , by Region K Tons (2017-2022)
  • Table 97. Human Endostatin Sales: by Application(K Tons)
  • Table 98. Human Endostatin Sales Medical Care , by Region K Tons (2017-2022)
  • Table 99. Human Endostatin Sales Scientific Research , by Region K Tons (2017-2022)
  • Table 100. Human Endostatin Sales Others , by Region K Tons (2017-2022)
  • Table 101. Human Endostatin Sales: by Distribution Channel(K Tons)
  • Table 102. Human Endostatin Sales Direct , by Region K Tons (2017-2022)
  • Table 103. Human Endostatin Sales Indirect , by Region K Tons (2017-2022)
  • Table 104. South America Human Endostatin Sales, by Country K Tons (2017-2022)
  • Table 105. South America Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 106. South America Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 107. South America Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 108. Brazil Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 109. Brazil Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 110. Brazil Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 111. Argentina Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 112. Argentina Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 113. Argentina Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 114. Rest of South America Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 115. Rest of South America Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 116. Rest of South America Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 117. Asia Pacific Human Endostatin Sales, by Country K Tons (2017-2022)
  • Table 118. Asia Pacific Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 119. Asia Pacific Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 120. Asia Pacific Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 121. China Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 122. China Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 123. China Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 124. Japan Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 125. Japan Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 126. Japan Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 127. India Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 128. India Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 129. India Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 130. South Korea Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 131. South Korea Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 132. South Korea Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 133. Taiwan Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 134. Taiwan Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 135. Taiwan Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 136. Australia Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 137. Australia Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 138. Australia Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 139. Rest of Asia-Pacific Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 140. Rest of Asia-Pacific Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 141. Rest of Asia-Pacific Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 142. Europe Human Endostatin Sales, by Country K Tons (2017-2022)
  • Table 143. Europe Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 144. Europe Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 145. Europe Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 146. Germany Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 147. Germany Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 148. Germany Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 149. France Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 150. France Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 151. France Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 152. Italy Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 153. Italy Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 154. Italy Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 155. United Kingdom Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 156. United Kingdom Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 157. United Kingdom Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 158. Netherlands Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 159. Netherlands Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 160. Netherlands Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 161. Rest of Europe Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 162. Rest of Europe Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 163. Rest of Europe Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 164. MEA Human Endostatin Sales, by Country K Tons (2017-2022)
  • Table 165. MEA Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 166. MEA Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 167. MEA Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 168. Middle East Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 169. Middle East Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 170. Middle East Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 171. Africa Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 172. Africa Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 173. Africa Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 174. North America Human Endostatin Sales, by Country K Tons (2017-2022)
  • Table 175. North America Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 176. North America Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 177. North America Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 178. United States Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 179. United States Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 180. United States Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 181. Canada Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 182. Canada Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 183. Canada Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 184. Mexico Human Endostatin Sales, by Type K Tons (2017-2022)
  • Table 185. Mexico Human Endostatin Sales, by Application K Tons (2017-2022)
  • Table 186. Mexico Human Endostatin Sales, by Distribution Channel K Tons (2017-2022)
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Human Endostatin: by Type(USD Million)
  • Table 198. Human Endostatin Idiopathic , by Region USD Million (2023-2028)
  • Table 199. Human Endostatin Paraneoplastic , by Region USD Million (2023-2028)
  • Table 200. Human Endostatin: by Application(USD Million)
  • Table 201. Human Endostatin Medical Care , by Region USD Million (2023-2028)
  • Table 202. Human Endostatin Scientific Research , by Region USD Million (2023-2028)
  • Table 203. Human Endostatin Others , by Region USD Million (2023-2028)
  • Table 204. Human Endostatin: by Distribution Channel(USD Million)
  • Table 205. Human Endostatin Direct , by Region USD Million (2023-2028)
  • Table 206. Human Endostatin Indirect , by Region USD Million (2023-2028)
  • Table 207. South America Human Endostatin, by Country USD Million (2023-2028)
  • Table 208. South America Human Endostatin, by Type USD Million (2023-2028)
  • Table 209. South America Human Endostatin, by Application USD Million (2023-2028)
  • Table 210. South America Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 211. Brazil Human Endostatin, by Type USD Million (2023-2028)
  • Table 212. Brazil Human Endostatin, by Application USD Million (2023-2028)
  • Table 213. Brazil Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 214. Argentina Human Endostatin, by Type USD Million (2023-2028)
  • Table 215. Argentina Human Endostatin, by Application USD Million (2023-2028)
  • Table 216. Argentina Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 217. Rest of South America Human Endostatin, by Type USD Million (2023-2028)
  • Table 218. Rest of South America Human Endostatin, by Application USD Million (2023-2028)
  • Table 219. Rest of South America Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 220. Asia Pacific Human Endostatin, by Country USD Million (2023-2028)
  • Table 221. Asia Pacific Human Endostatin, by Type USD Million (2023-2028)
  • Table 222. Asia Pacific Human Endostatin, by Application USD Million (2023-2028)
  • Table 223. Asia Pacific Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 224. China Human Endostatin, by Type USD Million (2023-2028)
  • Table 225. China Human Endostatin, by Application USD Million (2023-2028)
  • Table 226. China Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 227. Japan Human Endostatin, by Type USD Million (2023-2028)
  • Table 228. Japan Human Endostatin, by Application USD Million (2023-2028)
  • Table 229. Japan Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 230. India Human Endostatin, by Type USD Million (2023-2028)
  • Table 231. India Human Endostatin, by Application USD Million (2023-2028)
  • Table 232. India Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 233. South Korea Human Endostatin, by Type USD Million (2023-2028)
  • Table 234. South Korea Human Endostatin, by Application USD Million (2023-2028)
  • Table 235. South Korea Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 236. Taiwan Human Endostatin, by Type USD Million (2023-2028)
  • Table 237. Taiwan Human Endostatin, by Application USD Million (2023-2028)
  • Table 238. Taiwan Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 239. Australia Human Endostatin, by Type USD Million (2023-2028)
  • Table 240. Australia Human Endostatin, by Application USD Million (2023-2028)
  • Table 241. Australia Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 242. Rest of Asia-Pacific Human Endostatin, by Type USD Million (2023-2028)
  • Table 243. Rest of Asia-Pacific Human Endostatin, by Application USD Million (2023-2028)
  • Table 244. Rest of Asia-Pacific Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 245. Europe Human Endostatin, by Country USD Million (2023-2028)
  • Table 246. Europe Human Endostatin, by Type USD Million (2023-2028)
  • Table 247. Europe Human Endostatin, by Application USD Million (2023-2028)
  • Table 248. Europe Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 249. Germany Human Endostatin, by Type USD Million (2023-2028)
  • Table 250. Germany Human Endostatin, by Application USD Million (2023-2028)
  • Table 251. Germany Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 252. France Human Endostatin, by Type USD Million (2023-2028)
  • Table 253. France Human Endostatin, by Application USD Million (2023-2028)
  • Table 254. France Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 255. Italy Human Endostatin, by Type USD Million (2023-2028)
  • Table 256. Italy Human Endostatin, by Application USD Million (2023-2028)
  • Table 257. Italy Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 258. United Kingdom Human Endostatin, by Type USD Million (2023-2028)
  • Table 259. United Kingdom Human Endostatin, by Application USD Million (2023-2028)
  • Table 260. United Kingdom Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 261. Netherlands Human Endostatin, by Type USD Million (2023-2028)
  • Table 262. Netherlands Human Endostatin, by Application USD Million (2023-2028)
  • Table 263. Netherlands Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 264. Rest of Europe Human Endostatin, by Type USD Million (2023-2028)
  • Table 265. Rest of Europe Human Endostatin, by Application USD Million (2023-2028)
  • Table 266. Rest of Europe Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 267. MEA Human Endostatin, by Country USD Million (2023-2028)
  • Table 268. MEA Human Endostatin, by Type USD Million (2023-2028)
  • Table 269. MEA Human Endostatin, by Application USD Million (2023-2028)
  • Table 270. MEA Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 271. Middle East Human Endostatin, by Type USD Million (2023-2028)
  • Table 272. Middle East Human Endostatin, by Application USD Million (2023-2028)
  • Table 273. Middle East Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 274. Africa Human Endostatin, by Type USD Million (2023-2028)
  • Table 275. Africa Human Endostatin, by Application USD Million (2023-2028)
  • Table 276. Africa Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 277. North America Human Endostatin, by Country USD Million (2023-2028)
  • Table 278. North America Human Endostatin, by Type USD Million (2023-2028)
  • Table 279. North America Human Endostatin, by Application USD Million (2023-2028)
  • Table 280. North America Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 281. United States Human Endostatin, by Type USD Million (2023-2028)
  • Table 282. United States Human Endostatin, by Application USD Million (2023-2028)
  • Table 283. United States Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 284. Canada Human Endostatin, by Type USD Million (2023-2028)
  • Table 285. Canada Human Endostatin, by Application USD Million (2023-2028)
  • Table 286. Canada Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 287. Mexico Human Endostatin, by Type USD Million (2023-2028)
  • Table 288. Mexico Human Endostatin, by Application USD Million (2023-2028)
  • Table 289. Mexico Human Endostatin, by Distribution Channel USD Million (2023-2028)
  • Table 290. Human Endostatin Sales: by Type(K Tons)
  • Table 291. Human Endostatin Sales Idiopathic , by Region K Tons (2023-2028)
  • Table 292. Human Endostatin Sales Paraneoplastic , by Region K Tons (2023-2028)
  • Table 293. Human Endostatin Sales: by Application(K Tons)
  • Table 294. Human Endostatin Sales Medical Care , by Region K Tons (2023-2028)
  • Table 295. Human Endostatin Sales Scientific Research , by Region K Tons (2023-2028)
  • Table 296. Human Endostatin Sales Others , by Region K Tons (2023-2028)
  • Table 297. Human Endostatin Sales: by Distribution Channel(K Tons)
  • Table 298. Human Endostatin Sales Direct , by Region K Tons (2023-2028)
  • Table 299. Human Endostatin Sales Indirect , by Region K Tons (2023-2028)
  • Table 300. South America Human Endostatin Sales, by Country K Tons (2023-2028)
  • Table 301. South America Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 302. South America Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 303. South America Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 304. Brazil Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 305. Brazil Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 306. Brazil Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 307. Argentina Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 308. Argentina Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 309. Argentina Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 310. Rest of South America Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 311. Rest of South America Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 312. Rest of South America Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 313. Asia Pacific Human Endostatin Sales, by Country K Tons (2023-2028)
  • Table 314. Asia Pacific Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 315. Asia Pacific Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 316. Asia Pacific Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 317. China Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 318. China Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 319. China Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 320. Japan Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 321. Japan Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 322. Japan Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 323. India Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 324. India Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 325. India Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 326. South Korea Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 327. South Korea Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 328. South Korea Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 329. Taiwan Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 330. Taiwan Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 331. Taiwan Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 332. Australia Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 333. Australia Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 334. Australia Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 335. Rest of Asia-Pacific Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 336. Rest of Asia-Pacific Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 337. Rest of Asia-Pacific Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 338. Europe Human Endostatin Sales, by Country K Tons (2023-2028)
  • Table 339. Europe Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 340. Europe Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 341. Europe Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 342. Germany Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 343. Germany Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 344. Germany Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 345. France Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 346. France Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 347. France Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 348. Italy Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 349. Italy Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 350. Italy Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 351. United Kingdom Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 352. United Kingdom Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 353. United Kingdom Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 354. Netherlands Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 355. Netherlands Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 356. Netherlands Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 357. Rest of Europe Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 358. Rest of Europe Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 359. Rest of Europe Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 360. MEA Human Endostatin Sales, by Country K Tons (2023-2028)
  • Table 361. MEA Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 362. MEA Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 363. MEA Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 364. Middle East Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 365. Middle East Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 366. Middle East Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 367. Africa Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 368. Africa Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 369. Africa Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 370. North America Human Endostatin Sales, by Country K Tons (2023-2028)
  • Table 371. North America Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 372. North America Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 373. North America Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 374. United States Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 375. United States Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 376. United States Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 377. Canada Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 378. Canada Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 379. Canada Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 380. Mexico Human Endostatin Sales, by Type K Tons (2023-2028)
  • Table 381. Mexico Human Endostatin Sales, by Application K Tons (2023-2028)
  • Table 382. Mexico Human Endostatin Sales, by Distribution Channel K Tons (2023-2028)
  • Table 383. Research Programs/Design for This Report
  • Table 384. Key Data Information from Secondary Sources
  • Table 385. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Endostatin: by Type USD Million (2017-2022)
  • Figure 5. Global Human Endostatin: by Application USD Million (2017-2022)
  • Figure 6. Global Human Endostatin: by Distribution Channel USD Million (2017-2022)
  • Figure 7. South America Human Endostatin Share (%), by Country
  • Figure 8. Asia Pacific Human Endostatin Share (%), by Country
  • Figure 9. Europe Human Endostatin Share (%), by Country
  • Figure 10. MEA Human Endostatin Share (%), by Country
  • Figure 11. North America Human Endostatin Share (%), by Country
  • Figure 12. Global Human Endostatin: by Type K Tons (2017-2022)
  • Figure 13. Global Human Endostatin: by Application K Tons (2017-2022)
  • Figure 14. Global Human Endostatin: by Distribution Channel K Tons (2017-2022)
  • Figure 15. South America Human Endostatin Share (%), by Country
  • Figure 16. Asia Pacific Human Endostatin Share (%), by Country
  • Figure 17. Europe Human Endostatin Share (%), by Country
  • Figure 18. MEA Human Endostatin Share (%), by Country
  • Figure 19. North America Human Endostatin Share (%), by Country
  • Figure 20. Global Human Endostatin share by Players 2022 (%)
  • Figure 21. Global Human Endostatin share by Players (Top 3) 2022(%)
  • Figure 22. Global Human Endostatin share by Players (Top 5) 2022(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 26. Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan) Revenue: by Geography 2022
  • Figure 28. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 29. Thermo Fisher Scientific (United States) Revenue: by Geography 2022
  • Figure 30. Novus Biologicals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Novus Biologicals (United States) Revenue: by Geography 2022
  • Figure 32. Yantai Medgenn Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 33. Yantai Medgenn Co., Ltd. (China) Revenue: by Geography 2022
  • Figure 34. Intas Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 35. Intas Pharmaceuticals Ltd. (India) Revenue: by Geography 2022
  • Figure 36. Onyx Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Onyx Pharmaceuticals, Inc. (United States) Revenue: by Geography 2022
  • Figure 38. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 40. Biocon Limited (India) Revenue, Net Income and Gross profit
  • Figure 41. Biocon Limited (India) Revenue: by Geography 2022
  • Figure 42. PeproTech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. PeproTech, Inc. (United States) Revenue: by Geography 2022
  • Figure 44. Global Human Endostatin: by Type USD Million (2023-2028)
  • Figure 45. Global Human Endostatin: by Application USD Million (2023-2028)
  • Figure 46. Global Human Endostatin: by Distribution Channel USD Million (2023-2028)
  • Figure 47. South America Human Endostatin Share (%), by Country
  • Figure 48. Asia Pacific Human Endostatin Share (%), by Country
  • Figure 49. Europe Human Endostatin Share (%), by Country
  • Figure 50. MEA Human Endostatin Share (%), by Country
  • Figure 51. North America Human Endostatin Share (%), by Country
  • Figure 52. Global Human Endostatin: by Type K Tons (2023-2028)
  • Figure 53. Global Human Endostatin: by Application K Tons (2023-2028)
  • Figure 54. Global Human Endostatin: by Distribution Channel K Tons (2023-2028)
  • Figure 55. South America Human Endostatin Share (%), by Country
  • Figure 56. Asia Pacific Human Endostatin Share (%), by Country
  • Figure 57. Europe Human Endostatin Share (%), by Country
  • Figure 58. MEA Human Endostatin Share (%), by Country
  • Figure 59. North America Human Endostatin Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan)
  • Thermo Fisher Scientific (United States)
  • Novus Biologicals (United States)
  • Yantai Medgenn Co., Ltd. (China)
  • Intas Pharmaceuticals Ltd. (India)
  • Onyx Pharmaceuticals, Inc. (United States)
  • Novartis AG (Switzerland)
  • Biocon Limited (India)
  • PeproTech, Inc. (United States)
Additional players considered in the study are as follows:
Genexine, Inc. (South Korea) , EntreMed, Inc. (United States) , R&D Systems, Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2023 214 Pages 66 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Endostatin Quantitative research analysis
Global Human Endostatin Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer Inc. (United States), Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan), Thermo Fisher Scientific (United States), Novus Biologicals (United States), Yantai Medgenn Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Onyx Pharmaceuticals, Inc. (United States), Novartis AG (Switzerland), Biocon Limited (India) and PeproTech, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Medical Applications is the Most Dominant Segment" is seen as one of major influencing trends for Human Endostatin Market during projected period 2022-2028.
The Human Endostatin market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Human Endostatin Report?

Have a Query? Click Here

Other Related Reports

MRSA Antibiotics Comprehensive Study by Type (Vancomycin, Teicoplanin, Linezolid, Cubicin, Others), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmac...
$ 3350
Inulin Comprehensive Study by Application (Granola Bars, Frozen Desserts, Nutritional Beverage Powders, Beverages, Others), Industry Verticals (Food and Beverages, Pharmaceuticals, Others), Sales Cha...
$ 3450
Life Science Reagents Comprehensive Study by Type (Chromatography Reagents, In-vitro Diagnostics Reagents, Polymerase Chain Reaction Reagent Kits, Others), Application (Pharmaceutical, Biotechnology,...
$ 3800
Orlistat Comprehensive Study by Type (120mg, 60mg), Application (Weight-reducing Aid, Other), Distribution Channel (Retailer, Online, Others), Prescription Mode (Prescription Drugs, OTC drugs) Player...
$ 3500
Iron Chelation Drug Comprehensive Study by Type (Deferoxamine, Deferiprone, Deferasirox), Application (Transfusional Iron Overload, NTDT Caused Iron Overload), Distribution Channel (Online, Offline) ...
$ 3500
Saffron Tablets Comprehensive Study by Type (Sugar Coated Tablet, Film Coated Tablet, Other), Application (Pharmaceutical, Nutraceutical), End User (Hospital Pharmacy, Retail Pharmacies, Online Pharm...
$ 3500